Prior to joining Burrill & Company, Mr. Ferrara was Manager at GeneChem Management, Inc., a healthcare venture capital firm, where he led several syndicated investments in Canada and the United States. He also held interim operating positions in portfolio companies and worked closely with BioChem Pharma's CSO and business development team in sourcing and pursuing inlicensing opportunities, which led to two of BioChem's largest deals, having achieved approximately $95 million in business development transactions. Prior to joining the venture capital community, he was a financial analyst at Letko, Brosseau & Associates. He began his career in healthcare as a pharmacist at a private cancer treatment center in Toronto focusing on experimental therapies. Mr. Ferrara also completed graduate studies in the field of gene regulation and nuclear receptors, and studied the activity of various vitamin D analogs in collaboration with Hoffman La Roche. Mr. Ferrara completed his MBA in Finance and International Business and MSc in Physiology at McGill University, and his BSc in Biology and Genetics at the University of Toronto. He serves on the Boards of Directors of Agilix, CardioKine (observer), Spectral Genomics, and Nucleonics.